Asset
Ompenaclid
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05693142 | phase2_3 | active_not_recruiting | 2023-01-04 | 2026-09-01 | REGENXBIO Inc. | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) |
FDA applications (0)
This company has no applications containing this asset.